Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. is dated January 9, 2017. The document serves as a press release announcing the company's financial calendar for 2017. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company has no approved products for sale as of this date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. The document is strictly informational regarding future reporting dates.
Material Changes
No material financial changes or operational updates are reported in this filing. The content is limited to the scheduling of future financial disclosures.
Guidance, Outlook, and Risks
Financial Calendar 2017:
- February 20, 2017: Cash position as of December 31, 2016.
- March 15, 2017: Full-year 2016 results.
- April 28, 2017: First three months 2017 cash position.
- June 15, 2017: Annual General Meeting.
- July 28, 2017: First-half 2017 results.
- October 31, 2017: Nine months 2017 cash position.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties in research and development, clinical trial outcomes, and regulatory approvals. The company explicitly states that historical preclinical or clinical results may not predict future trial results. There is no obligation to update these statements.
Investor Verification Checklist
- Verify the actual cash position and full-year 2016 results when released on February 20 and March 15, 2017, respectively.
- Confirm the status of ongoing clinical trials for Viaskin Peanut and Viaskin Milk.
- Monitor for any changes to the announced financial calendar dates.
- Review the company's Form 20-F for detailed risk factors and historical financial data not included in this press release.